ASH 2024: Myeloma
Michael Tomasson, MD, discusses combining elranatamab with carfilzomib and dexamethasone in multiple myeloma.
Dr. Patel discusses PFS and MRD negativity results from the CARTITUDE-4 trial of cilta-cel versus standard of care in MM.
Dr. Callander discusses a study on selinexor, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Advertisement
An expert on site at ASH 2024 discusses the MRD negativity data from CARTITUDE-4.
Noa Biran, MD reviews a clinical trial of SPd for relapsed or refractory multiple myeloma.
Rahul Banerjee, MD, of the Fred Hutchinson Cancer Center, discusses notable studies in myeloma presented at ASH 2024.
Advertisement
Ide-cel demonstrated similar outcomes and toxicities among patients 70 years and older compared with younger patients.
Ide-cel achieved a CR rate of 80.6%, an ORR of 87.1%, and a MRD negativity rate of 66.7% in patients with myeloma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.